Adami H O, Björklund O, Enander L K, Gustavsson S, Lööf L, Nordahl A, Rosén A
Dig Dis Sci. 1982 May;27(5):388-93. doi: 10.1007/BF01295645.
Seventy-one patients with duodenal ulcer disease completed a 3- to 6-week controlled randomized trial in which cimetidine (1 g daily) was compared with an optimally effective dose of propantheline. Both groups had free access to an antacid suspension. There were no significant differences between the groups concerning ulcer healing, relief of ulcer symptoms, antacid consumption, or patient compliance. After 3 weeks of treatment, endoscopic examination revealed complete ulcer healing in 63% of the cimetidine and 47% of the propantheline treated patients. The corresponding figures after 6 weeks were 94% and 86%, respectively. After 12 weeks, ulcer recurrence was confirmed in 26% of the cimetidine- and 23% of the propantheline-treated patients. Except for the absence of anticholinergic adverse reactions, no significant advantages could be confirmed for combined cimetidine and antacid treatment.
71名十二指肠溃疡患者完成了一项为期3至6周的对照随机试验，该试验将西咪替丁（每日1克）与最佳有效剂量的丙胺太林进行了比较。两组患者均可自由使用抗酸剂混悬液。两组在溃疡愈合、溃疡症状缓解、抗酸剂消耗量或患者依从性方面均无显著差异。治疗3周后，内镜检查显示，接受西咪替丁治疗的患者中有63%溃疡完全愈合，接受丙胺太林治疗的患者中这一比例为47%。6周后的相应数字分别为94%和86%。12周后，接受西咪替丁治疗的患者中有26%溃疡复发，接受丙胺太林治疗的患者中这一比例为23%。除了没有抗胆碱能不良反应外，西咪替丁与抗酸剂联合治疗未显示出明显优势。
